Effective January 1, 2022
According to STORE Manual, 2022 edition, STandards for Oncology Registry Entry (STORE v2022) (facs.org), the STORE, Standards for Oncology Registry Entry, was developed in 2014 by a group of professional Cancer Registrars, “representing CoC accredited hospitals, state registries, the SEER program of National Cancer Institute”, as well as many physicians who represented “surgical oncology, medical oncology and radiation oncology.” These physicians ensured “that diagnostic and treatment codes were updated and reflected current practice. The manual took four years to develop.” This coding structure is vital to hospital registry data that is entered into the NCDB and determines the CoC quality measures which are currently being used in Rapid Quality Reporting System (RQRS), Cancer Quality Improvement Program (CQIP), and the CP’R Program which tracks quality within all of the CoC-accredited institutions. In 2018, The new STORE Manual was released and has seen a few changes throughout the years to ensure every field is coded in accordance with other manual changes. In April 2021, the “American College of Surgeons” and the “Commission on Cancer,” released the new changes to the STORE Manual for all cases Diagnosed, January 1, 2022, and forward. These changes coincide with the changes made to the Solid Tumor Rules, ICD-0-3 manual, and other registry manuals.
One significant change to the STORE Manual, affects abstracting for all cancer sites. For 2022, it is not necessary that registrars record if a patient was tested for COVID, and the effects on the outcome on diagnosis and treatment.
While some changes apply to all cancer sites, a majority of changes affect specific sites. One such change affects “lymphovascular invasion word changes” “for thyroid and adrenal cancers.” This change came about due to cancer registrars questioning “CAP protocols” to pathologists based on the specific wording in comparison to the site. Two codes were modified to reflect the wording changes for cases involving thyroid, thyroid medullary, and adrenal gland cancers. In this case, Code 2 states “Lymphatic and small vessel invasion only (I.) OR “Lymphatic invasion only (thyroid and adrenal only) while Code 3 states “Venous (large vessel) invasion only (V) OR Angioinvasion (thyroid and adrenal only).
The STORE Manual lists a summary of all the changes for 2022 on pages 28-34. Some of these changes include only word changes, while others affect specific code changes. Many of these coding instructions represent “reportability changes” for specific histologies that were reflected in the ICD-0-3 manual. Some code changes include codes no longer used, for surgery codes that are no longer being used, due to “obsolete treatments” for rectal and anal cancers. One final code change is the use of “Code 64” for prostate. This code is used to represent “whole” prostate, while the new change reflects “Prostate with/without seminal vesicles.
Although the STORE Manual summary of changes includes a list of changes from several manuals, it is important to review each manual to get a full, complete listing of all changes made in each manual.
For a complete listing of all changes made to the STORE Manual go to, STandards for Oncology Registry Entry (STORE v2022) (facs.org).
Leave a Reply
Your email address will not be published. Required fields are marked *